Hepcidin and iron regulation, ten years later

Tomas Ganz

Departments of Medicine and Pathology

David Geffen School of Medicine at UCLA

Los Angeles, CA 90095

E-mail: Tganz@mednet.ucla.edu

Abstract

Under evolutionary pressure to counter the toxicity of iron and to maintain adequate iron supply for hemoglobin synthesis and essential metabolic functions, humans and other vertebrates have effective mechanisms to conserve iron and to regulate its concentration, storage and distribution in tissues. The iron-regulatory hormone hepcidin, first described ten years ago, and its receptor and iron channel ferroportin control the dietary absorption, storage and tissue distribution of iron. Hepcidin causes ferroportin internalization and degradation, thereby decreasing iron transfer into blood plasma from the duodenum, from macrophages involved in recycling senescent erythrocytes, and from iron-storing hepatocytes. Hepcidin is feedback regulated by iron concentrations in plasma and the liver, and by erythropoietic demand for iron. Genetic malfunctions affecting the hepcidin-ferroportin axis are a major cause of iron overload disorders but can also cause iron-restricted anemias. Modulation of hepcidin and ferroportin expression during infection and inflammation couples iron metabolism to host defense and decreases iron availability to invading pathogens. This response also restricts the iron supply to erythropoietic precursors and may cause or contribute to the anemia associated with infections and inflammatory disorders.
Overview

This review, occasioned by the tenth anniversary of the first publications on hepcidin\textsuperscript{1-4}, focuses on the central role of hepcidin and its receptor/iron exporter ferroportin in the regulation of iron absorption, recycling and tissue distribution in health and disease. A complementary overview of iron pathobiology was published in this journal two years ago\textsuperscript{5}.

Brief History

Already in the 1930s, McCance and Widdowson estimated intestinal iron absorption by subtracting the iron content of feces and urine from the iron content of the diet (see Supplemental Data for references prior to year 2000). They noted that iron absorption was increased in iron-deficient subjects. There was no change in iron excretion when already replete subjects were given parenteral iron, indicating that excretion was not regulated. Hahn and Whipple analyzed the kinetics of intestinal radioiron absorption and utilization in humans and animal models, and confirmed that absorption was regulated and there was no significant excretion of iron. In the 1950s, Finch and Saylor established that iron absorption was also stimulated by increased erythropoietic activity, and suppressed by hypertransfusion. The recycling of hemoglobin from damaged radioiron-labeled erythrocytes into iron was measured by Noyes, Bothwell and Finch. More iron was released from the reticuloendothelial system when patients or experimental animals were iron-deficient, indicating that the release of iron from macrophages was regulated by iron stores. Freireich, Wintrobe, Cartright, Finch and others showed that inflammation induced the sequestration of iron in macrophages of the liver and the spleen (the “reticuloendothelial” system) and inhibited the supply of iron to erythropoiesis, causing anemia.

Beutler et al. anticipated in 1960 that a humoral substance matched the absorption of iron (and by extension, its release from stores) to the iron demands of erythropoiesis, and Krantz et al. showed that this substance was not erythropoietin.

In the 1960s, Manis and Schachter, and Wheby et al. showed in isolated intestinal loops that iron absorption took place in the proximal duodenum and was regulated in two steps: uptake of iron into enterocytes (“mucosal uptake”), followed either by cytoplasmic iron storage in ferritin, or by the release of iron into the blood circulation (“mucosal transfer”). Because the lifespan of enterocytes is a few days, the fate of dietary iron taken up by enterocytes would be determined by the regulated basolateral iron transporter(s): either the absorbed iron was allowed to enter blood circulation, or it would be returned into the intestinal lumen with the dying enterocytes, as they shed into the fecal stream.

In the 1970s, investigators reexamined the pathogenesis of hereditary hemochromatosis, a syndrome in which excessive iron was deposited in the liver and other tissues, with resulting tissue injury, organ failure and hepatic carcinogenesis. Powell et al. noted that the disorder exhibited features in common with iron deficiency: increased intestinal iron absorption with increased mucosal transfer (i.e. increased basolateral iron transport from enterocytes to plasma) and depleted ferritin in enterocytes and macrophages. Weatherall’s group reported that
similar pathogenic mechanisms were responsible for iron overload in \( \beta \)-thalassemia intermedia where hyperabsorption was related to ineffective erythropoiesis and intense erythropoietic stimulation.

The 1990s witnessed a renaissance of iron pathobiology. Investigations of patients and animal models with genetic iron disorders led to the identification of genes that encoded iron transporters, transport-related oxidoreductases, and iron regulatory molecules.

**Hepcidin, the iron-regulatory hormone**

The iron hormone was not found by the genetic methods, in retrospect because of the small size of its gene, the corresponding rarity of its random mutations, and the lack of sequence motifs shared with known iron-related genes. Multiple serendipitous events helped identify hepcidin and its function in iron homeostasis. While purifying from human urine \( \beta \)-defensin-1, a kidney-produced innate immunity peptide, we found a new defensin-like peptide which contained 25 amino acids and four disulfide bonds. In January 1998, we deposited the sequence of this peptide to Swiss Prot database, and named it hepcidin because its mRNA was highly expressed in the liver and the peptide showed weak microbicidal activity *in vitro*. We also noticed that hepcidin concentration was increased more than a hundred-fold in the urine of a septic donor, linking the peptide to inflammation and innate immunity. Krause et al. independently isolated the same peptide from hemodialysate. The first iron connection emerged in studies by Pigeon et al. who were searching for genes overexpressed in the liver of mice overloaded with iron. They identified hepcidin mRNA as an iron-induced transcript and also showed that the mRNA was increased by inflammation. Soon after in 2001, the function of hepcidin as an iron regulator was demonstrated by Nicolas, Vaulont et al. who noticed that the \( USF2 \) knockout mouse, generated for another purpose, had severe iron overload. The targeted \( USF2 \) gene was known to be adjacent to the gene encoding hepcidin, and the authors showed that \( USF2 \) disruption also severely suppressed hepcidin transcription. As noted by the authors and the accompanying editorial, hepcidin became the leading candidate for the long sought iron-regulatory hormone. The function of this peptide in innate immunity, suggested by its connection to antimicrobial peptides and inflammation, still remains to be explored, but may turn out to be related to its ability to lower the concentration of extracellular iron, a nutrient whose availability can limit the rate of multiplication of invading microbes.

Unlike humans, the mice have two hepcidin genes, located respectively next to \( USF2 \) and its partially duplicated pseudogene: hepcidin-1, a gene closely related to human hepcidin, and hepcidin-2, a divergent gene. To clarify the involvement of \( USF2 \) and the two hepcidin genes in iron regulation, Nicolas, Lou et al. constructed transgenic mice that overexpressed either hepcidin-1 or hepcidin-2 in their hepatocytes. Most mice overexpressing hepcidin-1 died of severe iron deficiency anemia shortly after birth, indicating that hepcidin-1 overexpression inhibited placental iron transport from the mother to the affected fetus. The few mosaic survivors remained severely iron-deficient after birth, indicating that their duodenal iron absorption was also inhibited. In contrast, mice transgenic for hepcidin-2, and mice with an alternative method for ablating \( USF2 \), showed no iron abnormalities excluding a major role of these genes in iron regulation. The authors next demonstrated that hepcidin-1 was suppressed by phlebotomy and
hemolysis, an important indication that it was the hormone that released iron to meet the needs of erythropoiesis.

Roetto et al. identified two rare families with the severe, juvenile form of hereditary hemochromatosis, and the affected members were homozygous for destructive hepcidin mutations, confirming that the hepcidin gene encoded the iron-regulatory hormone in humans. To demonstrate that the predicted 25 amino acid mature peptide product of the hepcidin gene possessed iron-regulatory activity, we synthesized and refolded the four disulfide form of human hepcidin-25 and showed that its parenteral administration induced prolonged and severe hypoferremia in mice.

**Ferroportin is the hepcidin receptor**

Ferroportin, identified in 2000 by three groups using distinct approaches, is the iron exporter on macrophages and on the basolateral membrane of duodenal enterocytes. Based on the demonstrated importance of mucosal transfer for the regulation of absorption, ferroportin was a natural candidate for the target of hepcidin, either directly or through a separate receptor and signaling pathway. The Kaplan group constructed a cell line that inducibly expressed a ferroportin-GFP fusion construct that localized to the cell membrane, and we collaborated to examine the effect of hepcidin on these cells. After exposure of the cells to hepcidin, the ferroportin-GFP fusion protein was internalized within less than an hour and soon after degraded. Radiolabeled hepcidin specifically bound to ferroportin-expressing but not to control cells, and could be competed with unlabeled hepcidin but not with truncated hepcidin-20 or an unrelated cationic peptide, protegrin. Ferroportin therefore was not only the hepcidin-regulated iron exporter but was itself the receptor for hepcidin, and the binding of hepcidin to ferroportin directly induced the endocytosis of ferroportin and its proteolysis in lysosomes. This mechanism explained how hepcidin decreased the export of iron from enterocytes, macrophages and placental cells into plasma. The ability of hepcidin to induce the endocytosis of ferroportin and reduce iron export was confirmed in a macrophage cell line where iron was delivered by erythrophagocytosis of Fe-labeled red cells. The structural determinants and details of hepcidin-induced ferroportin endocytosis and signaling are subjects of intense investigation but a definitive model has not yet emerged, in part due to the difficulties of obtaining structural information on ferroportin. The expression and activity of other iron-transport molecules, such as the apical and vacuolar iron transporter DMT-1, is also affected by hepcidin but these effects may be indirect and their mechanism remains to be elucidated.

*In vivo*, iron transfer from cells to plasma was completely dependent on ferroportin, as demonstrated by Donovan, Andrews and colleagues in studies of mice with ferroportin inactivation. Mice with global ferroportin inactivation died during embryonic development. If ferroportin expression at the maternal-fetal interface was selectively preserved, the mice were born but rapidly developed severe iron deficiency anemia in proportion to the completeness of ferroportin inactivation. Despite severely iron-restricted erythropoiesis, iron accumulated in enterocytes, macrophages and hepatocytes, indicating that ferroportin is essential for iron transfer to plasma, and that ferroportin decrease allows iron to be safely stored in the cytoplasmic ferritin of macrophages and hepatocytes.
Although ferroportin is found already in plants and worms, hepcidin and the conserved cysteine-containing hepcidin-binding loop in ferroportin are a vertebrate development. Other forms of ferroportin regulation should exist in invertebrates and plants but these have not yet been analyzed. However, hepcidin-independent regulation is also functionally important in vertebrates. Ferroportin expression was shown to be regulated translationally by intracellular iron through the IRE/IRP system and transcriptionally by heme, and these responses allow macrophages to match their iron export capacity to the fluctuating iron and heme load caused by episodic erythrophagocytosis. There are two major isoforms of ferroportin: FPN 1A, with a 5'IRE for translational repression in iron-deficient cells, and FPN 1B, lacking this motif. FPN 1B is expressed in duodenal enterocytes where it may allow them to export iron to the rest of the organism even if the enterocytes become iron-deficient.

Studies of patients with human ferroportin mutations provided important information about this molecule. Ferroportin mutations most often cause autosomal dominant “ferroportin disease”, manifested as loss of ferroportin function, iron accumulation in macrophages with very high levels of serum ferritin, but mild if any liver injury. Rare ferroportin mutations cause gain of function due to resistance to hepcidin, with parenchymal iron overload similar to that seen in classical hereditary hemochromatosis. Importantly, so far all mutations in ferroportin disease in humans and in mouse models were missense, suggesting that haploinsufficiency due to heterozygous nonsense mutations does not decrease ferroportin activity enough to result in ferroportin disease. If most loss-of-function mutations give rise to trafficking defects, ferroportin multimerization with mistrafficking of complexes that contain a mutated copy would lead to a dominant negative effect. This simple and attractive model has been contested by multiple investigators who did not detect multimerization or a trafficking defect in a variety of loss-of-function mutants, as recently summarized. Alternatively, some mutations may cause an iron transport defect whose impact could be increased if the mutant ferroportin molecules trigger endocytosis that also entrains wild-type ferroportin.

The structure of ferroportin has not yet been elucidated, in part because it is a multipass transmembrane molecule without any close structurally-characterized homologs. The best supported ferroportin model has 12 transmembrane segments with both termini located intracellularly. Despite the importance of ferroportin, it is still not known how it transports iron. The dependence of iron export on extracellular ferroxidase activity suggests that ferroportin allows ferrous iron to transit along its gradient of concentration.

The hepcidin-ferroportin interaction controls systemic iron homeostasis

Hepcidin, acting on ferroportin, controls the major inflows of iron into plasma: from duodenal enterocytes absorbing dietary iron, from macrophages involved in the recycling of iron from senescent erythrocytes and other cells, and from hepatocytes involved in iron storage (Figure 1). During pregnancy, fetal hepcidin controls the placental transfer of iron from maternal plasma to the fetal circulation. When hepcidin concentrations are low, iron enters blood plasma at a high rate. When hepcidin concentrations are high, ferroportin is internalized and iron is trapped in enterocytes, macrophages and hepatocytes. Plasma iron concentrations and transferrin saturation reflect the difference between the hepcidin/ferroportin-regulated transfer of iron to plasma and iron consumption by the erythropoietic bone marrow and, to a lesser extent, other
tissues. The plasma transferrin compartment is relatively small and its iron content therefore turns over every 3 hours or so, allowing iron concentrations to respond rapidly to changes in hepcidin concentrations.

The role of hepcidin in regulating the absorption of dietary heme, the major form of absorbable iron in human and other carnivore diets, has not been experimentally examined. To the extent that heme is metabolized to ferrous iron within enterocytes, its transfer to plasma would still depend on ferroportin and would therefore be subject to hepcidin regulation.

**Hepcidin regulation by iron**

Hepcidin is feedback-regulated both by iron concentrations and by the erythropoietic requirements for iron. In mouse models, hepcidin-1 mRNA was shown to be induced by iron loading\(^3,^9\) and suppressed by anemia and hypoxia\(^9\). Because additional levels of regulation were possible prior to secretion of the bioactive peptide it was important to establish how the levels of circulating hepcidin are regulated. However, the production of high quality anti-hepcidin antibodies for immunoassays of human or mouse hepcidin proved difficult so initial immunoassays relied on estimation of hepcidin in urine. Hepcidin was decreased or absent in iron deficiency, increased by transfusion-induced iron overload and inflammatory diseases, and in general showed high correlation with serum ferritin levels\(^25\). An oral load of 65 mg iron in healthy volunteers caused more than five-fold increase in hepcidin within 1 day\(^26\). Improvement in immunochemical and mass spectrometric hepcidin assays allowed the detection of hepcidin in serum. The assays established that hepcidin transiently rises about 4-8h after oral iron administration and that it is subject to diurnal variation with a mid-day maximum, perhaps due to dietary iron ingestion\(^27,^28\). The responsiveness of blood hepcidin concentrations to dietary iron may be increased by the dual blood supply of the liver from the portal and systemic circulation which may allow diferric transferrin from the portal circulation to be sensed as it delivers boluses of dietary iron.

Do hepatocytes sense iron and regulate hepcidin production on their own or in response to signals from other cell types that sensed iron concentrations? Although other cell types may influence hepcidin production, in vitro studies indicate that isolated hepatocytes contain iron sensors as well as the transduction apparatus required for regulating hepcidin synthesis. First attempts to replicate hepcidin regulation by iron in isolated hepatocytes showed no stimulation or even suppression of hepcidin mRNA by iron loading\(^25,^29\) probably because these cells underwent rapid phenotypic change in culture and lost their ability to express characteristic hepatic proteins. Hepatocyte-derived cell lines also showed a paradoxical decrease in hepcidin mRNA after treatment with iron or transferrin\(^25\). However, freshly harvested mouse hepatocytes did increase their hepcidin-1 mRNA after treatment with physiologic concentrations of holotransferrin\(^30,^31\). It appears, however, that apart from diferric transferrin which may induce rapid hepcidin responses on the time scale of hours\(^27\), other forms of iron are involved in hepcidin regulation in response to chronic iron loading, perhaps sensed as hepatic cellular iron stores (Ramos et al., Hepatology, in press).
Molecular mechanisms of hepcidin regulation by iron: a current model

Hepcidin is transcriptionally regulated\(^{32}\), with as yet no evidence of other types of control. Naturally occurring human mutations and transgenic mouse models have provided valuable information about the molecules involved in hepcidin regulation, and, together with biochemical studies, have yielded insights into their interactions. In general, mutations in regulatory molecules cause either hepcidin deficiency resulting in iron overload, or hepcidin excess with consequent iron deficiency and sequestration. HFE, transferrin receptor 2 (TfR2) and hemojuvelin (HJV) (Table I with references) are genes mutated in human hemochromatosis, and their ablation results in decreased hepcidin responsiveness to iron, and relative or absolute hepcidin deficiency. Conversely, mutations in the protease TMPRSS6, which are associated with severe iron deficiency, prevent the appropriate decrease of hepcidin in the face of iron deficiency. Mouse models of hemochromatosis revealed that components of the BMP pathway are also necessary for hepcidin regulation by iron: BMP6 as well as liver-specific Smad4 knockout mice also developed severe iron overload and had inappropriately low hepcidin mRNA levels. Furthermore, the production of BMP6 is increased when liver iron concentrations are high, suggesting that BMP6 may be a signal reflecting iron stores. The task of understanding hepcidin regulation by iron is made more difficult by the apparent redundancy in the system. The combined effect of HFE and TfR2 ablation is much more severe than the effect of the loss of either molecule\(^{33,34}\). Moreover, although each mutation has a profound effect on hepcidin response to acute iron loading, individual ablation of HFE, TfR2, hemojuvelin or BMP6 only partially impairs the hepcidin increase in response to chronic iron loading. Additionally, the ablation of HFE, TfR2 or hemojuvelin has no detectable effect on BMP6 regulation by iron, indicating that a separate mechanism is responsible for iron-dependent regulation of BMP6 (Ramos et al., Hepatology in press). Based on the work by many groups, a model of hepcidin regulation by iron has emerged (Figure 2) in which: 1) the BMP receptor and its signaling components are at the core of the regulatory mechanism and control the transcription of hepcidin thorough the Smad pathway, 2) hemojuvelin is an iron-specific adaptor-ligand of the BMP receptor that increases its sensitivity to BMPs, 3) information about hepatic iron stores is conveyed though increased production of BMP6, an activating ligand of the BMP receptor, 4) extracellular iron concentration is sensed through the interaction of holotransferrin with TfR1 and TfR2, with HFE as an intermediary between the two molecules, 5) TfR2 and HFE increase the sensitivity of the BMP receptor to its ligands in an holotransferrin-dependent manner, perhaps by interactions with hemojuvelin, 6) TMPRSS6, perhaps stabilized by iron deficiency, cleaves membrane hemojuvelin and inactivates it, and 7) other pathways participate in hepcidin regulation by iron. While many components of the hepcidin-regulatory apparatus have been identified (Table 1), the list is probably incomplete and much more remains to be learned about how the various components physically interact to modulate hepcidin transcription.

Hepcidin regulation by erythropoiesis

In hemorrhagic or hemolytic anemia, both iron absorption in the duodenum and the release of iron from stores are greatly increased, consistent with the effect that would be expected from a hepcidin decrease. Nicolas et al. observed that hepatic hepcidin mRNA in the mouse model was indeed suppressed by anemia, and proposed that the increased absorption and mobilization of
iron in anemia was mediated by the hypoxic suppression of hepcidin. In principle, at least three signals could mediate the erythropoietic suppression of hepcidin production. Anemia decreases oxygen tension in organs with high oxygen requirements potentially regulating hepcidin through hypoxia-inducible factors, similarly to erythropoietin regulation. In addition, increased demand for iron by erythropoietin-stimulated marrow could cause transient hypoferremia and suppress hepcidin through an iron-regulatory mechanism. Thirdly, there is evidence for bone marrow derived factors (“erythroid regulators”) that communicate the activity of the erythropoietic system to other organs. Although some contribution of hypoxia is likely, it now appears that the predominant signal is dependent on bone marrow activity, as ablation of the bone marrow in anemic mice reverses the hepcidin-suppressive effect of anemia.

Hepcidin regulation by inflammation

Inflammation has a potent effect on iron homeostasis, reducing intestinal iron absorption, sequestering iron in macrophages, and thereby decreasing serum iron levels. There is now substantial evidence that these effects of inflammation are also mediated by hepcidin. Wild-type mice increased hepcidin-1 mRNA and developed hypoferremia in response to turpentine-induced inflammation but in USF2/Hamp KO mice the hypoferremic response was lost. These experiments were confounded by the severe iron overload in Hamp KO mice which could by itself provide enough iron to relieve hypoferremia, so they need to be replicated in hepcidin-deficient humans or Hamp KO mice that are depleted of iron. In favor of the role of hepcidin in inflammatory hypoferremia, IL-6 and supernatants of LPS-stimulated macrophages readily induced hepcidin in human hepatocytes and hepatic cell lines. Moreover, urinary hepcidin level rose within hours of IL-6 or LPS infusion into human volunteers, on the average more than 7-fold, and hypoferremia coincided with the rise of hepcidin. The stimulatory effect of IL-6 on hepcidin is transcriptional and dependent on STAT3 interactions with a STAT3-binding element in the hepcidin promoter. Other cytokines and direct effects of microbial molecules on hepatocytes may also contribute to the inflammatory increase in hepcidin.

Primary disorders of hepcidin and ferroportin regulation

Overview—The discovery of hepcidin and its role in iron homeostasis remarkably simplified and rationalized our understanding of the pathogenesis of the most common iron disorders (Table 2). In the following discussion, I designate as “primary” those disorders that result from lesions in the genes that encode hepcidin, ferroportin or their physiologic regulators, and as “secondary” those disorders that are caused by diseases that originate outside of the iron-homeostatic system.

Hepcidin deficiency—Hereditary hemochromatoses (HH) are a group of genetic disorders characterized by excessive absorption of dietary iron, and its deposition in the liver and other organs. Liver injury leading to cirrhosis and hepatocellular carcinoma is a common clinical manifestation of HH but iron toxicity can also damage other organs. The most common form of HH in populations of Northern or Central European ancestry is caused by homozygous or compound heterozygous mutations in HFE, a gene encoding a membrane protein related to histocompatibility antigens. This form is often mild and incompletely penetrant, with phenotypic expression depending on gender, alcohol consumption, and other genetic and environmental
factors. A rare but possibly more severe form is due to autosomal recessive mutations in transferrin receptor 2 (TfR2). Also rare but very severe “juvenile” HH is an early onset disease with prominent cardiac and endocrine involvement, and is caused by autosomal recessive mutations in hemojuvelin (HJV) or hepcidin (HAMP). The common feature of all these genetic disorders is hepcidin deficiency, mildest in HFE disease and more severe or complete in the others. Hepcidin deficiency and iron accumulation in the liver and other organs are recapitulated in the corresponding mouse models but mice appear resistant to the toxic effects of iron. Transgenic expression of hepcidin prevented iron overload in mouse HFE model\textsuperscript{42}, confirming the pathogenic role of hepcidin deficiency. Apart from the genes involved in human HH, heritable iron overload in mice (as yet without known clinical equivalents in humans) is also caused by ablation of the gene encoding the bone morphogenetic protein 6 (Bmp6) and the gene encoding Smad4, a common signaling component of the BMP and TGFβ pathways.

At first glance it is puzzling why HH hepatocytes are iron-overloaded despite expressing ferroportin, while enterocytes and macrophages are iron-depleted, consistent with high expression of ferroportin and increased iron export from these cells. The iron loading of hepatocytes may be a consequence of their ability to take up increased plasma iron, especially in its non-transferrin bound forms, in excess of their ability to export it, so hepatocytes end up as the predominant iron storage organ in HH. The distribution of excess iron to other tissues probably reflects their respective avidity for non-transferrin iron.

**Resistance to hepcidin**—A very rare disease similar to HH is caused by autosomal dominant mutations in ferroportin that cause resistance to hepcidin. Of several ferroportin mutations that give rise to this syndrome, the one best characterized is C326S which causes early onset parenchymal iron overload with documented high or high-normal hepcidin levels\textsuperscript{43}. In these patients, the ferroportin mutation interferes with hepcidin binding\textsuperscript{44} but other mutations with a similar, but apparently less severe, phenotype may impair hepcidin-induced internalization of ferroportin by an as yet unknown mechanism.

**Hepcidin excess**—A primary human iron disorder with the opposite phenotype to HH is caused by mutations in the gene encoding the membrane serine protease matriptase 2 (also called TMPRSS6). Genetic impairment of this enzyme in mice or humans causes iron-refractory iron-deficiency anemia (IRIDA). The defining feature of this disorder are high-normal or high serum hepcidin concentrations\textsuperscript{45-47} despite severe iron deficiency. Increased hepcidin levels are presumably due to increased BMP signaling resulting from the inability of mutated TMPRSS6 to cleave membrane hemojuvelin\textsuperscript{48}. Milder heterozygous defects in TMPRSS6 may be common and could predispose to iron deficiency\textsuperscript{49,50}.

**Hypotransferrinemia**—Although transferrin deficiency affects predominantly the delivery of iron to erythropoiesis, a process entirely dependent of transferrin-mediated iron uptake, certain features of this disorder point to the direct involvement of transferrin in hepcidin regulation. The affected patients and mouse models (hp) show severe microcytic hypochromic anemia with parenchymal iron overload and severe hepcidin deficiency, with transferrin infusions correcting the anemia and raising hepcidin levels\textsuperscript{51}. In principle, hepcidin deficiency in this disease could be caused either by decreased stimulation of the iron sensors that regulate hepcidin production, or by the suppressive effects of erythropoietin-stimulated bone marrow on hepcidin production.
Experiments in which the contribution of the erythropoietic factor is negated by transfusions or bone marrow ablation, support the existence of both mechanisms.52

**Secondary disorders of hepcidin and ferroportin regulation**

**Iron-loading anemias**—Iron overload is the major cause of morbidity and mortality in anemias with ineffective erythropoiesis, including β-thalassemias and congenital dyserythropoietic anemias. In these disorders, ineffective but greatly expanded erythropoiesis is stimulated by high levels of erythropoietin. Severe iron overload resembling juvenile hereditary hemochromatosis can develop even in patients who are rarely or never transfused, indicating that dietary iron is hyperabsorbed in these conditions. Hepcidin concentrations in the untransfused patients with these disorders were very low, despite high serum ferritins and liver biopsies indicative of severe iron overload. Transfusions raise hepcidin likely because of the lowering of erythropoietin and erythroid activity in the bone marrow and further iron loading. Hepcidin synthesis in the liver is thought to be suppressed by one or more mediators produced during ineffective erythropoiesis. Recent studies provide evidence for the hepcidin-suppressive role of the BMP-family member GDF-15 in iron loading anemias which may be generated during apoptosis of erythroid progenitors. GDF-15, however, is not the physiologic mediator of iron hyperabsorption after blood loss.

**Chronic liver diseases**—Hepcidin deficiency with hepatic iron overload can complicate several chronic liver diseases, most prominently chronic hepatitis C and alcoholic liver disease. In chronic hepatitis C, hepatic iron accumulation may worsen prognosis and iron depletion has been reported to be beneficial. The mechanisms that impair hepcidin production in these disorders are being investigated.

**Chronic kidney diseases**—Hepcidin is in part eliminated by glomerular filtration and degradation in the proximal tubules, causing blood hepcidin concentrations to rise with diminishing renal function. The mechanism may contribute to the characteristic anemia as well as to erythropoietin resistance in chronic kidney disease.

**Anemia of inflammation (AI)**—The combination of mild to moderate anemia and hypoferrremia is often seen in chronic infections, inflammatory disorders, hematologic malignancies and some solid tumors. AI has also been called “anemia of chronic disease” although it often develops rapidly and is not seen in most chronic diseases. At its core, AI is a systemic iron disorder in which iron is sequestered in macrophages, intestinal iron absorption is decreased and hemoglobin synthesis is impaired due to limitations of iron delivery to the maturing erythrocytes. The condition in which iron stores are adequate but not available for hemoglobin synthesis is referred to as “iron restriction” in contrast to iron deficiency where stores are depleted. The inflammatory redistribution of iron can be explained by cytokine-stimulated hepcidin increase that leads to the loss of ferroportin from macrophage and enterocyte cell membranes, and the consequent trapping of iron in these cells. Among the cytokines that stimulate hepcidin synthesis, IL-6 and BMP-2 may be of particular clinical importance. Increased serum hepcidin concentrations have been found in acute infections, malaria, inflammatory diseases, multiple myeloma, Hodgkin disease, Castleman disease, and in a subset of patients with solid tumors. It is notable that in the IRIDA syndrome, relatively mild increases
in hepcidin concentration are sufficient to sustain an iron-restricted anemia, even with parenteral iron supplementation (Ganz et al., unpublished). Similar mild increases in hepcidin could perpetuate AI once it is established. The differences in erythrocyte morphology in the two disorders (AI is usually normocytic, IRIDA is severely microcytic) may be due to the direct effects of inflammatory cytokines on erythropoiesis. Depending on the underlying disease, other mechanisms including shortened erythrocyte lifespan or mildly impaired erythropoietin production may also contribute to this disorder.

**Diagnostic and therapeutic implications**—Immunochemical and mass-spectrometric assays of serum hepcidin are available for research purposes and an international effort is underway to achieve their standardization. Hepcidin assays would be particularly attractive for the diagnosis of iron-refractory iron deficiency anemia and the diagnosis and risk stratification of hereditary hemochromatosis because hepcidin dysregulation is the cause of these disorders, and genetic tests are often inconclusive. Hepcidin assays may aid in the diagnosis of iron deficiency anemia and anemia of inflammation, probably in combination with existing diagnostic modalities. The assays may also help guide the treatment of anemias with iron, erythropoietin, anti-cytokine therapies, intensification of hemodialysis as well as future drugs targeted at hepcidin or ferroportin. Future uses of the assay in clinical medicine may be facilitated by the clinical validation of indices (e.g. hepcidin/ferritin ratio for the diagnosis of hereditary hemochromatosis) that assess whether alterations in hepcidin levels are “appropriate” physiological responses to iron load, erythropoietic activity, or inflammation, or result from the pathological impairment of hepcidin responses to one of its regulators (Table 2). Such indices may also avoid the diagnostic uncertainties caused by the wide normal range of hepcidin which are due to variations in iron stores and perhaps inflammation even in apparently healthy subjects.

On the therapeutic front, hepcidin agonists or stimulators of hepcidin production are being developed for the treatment or prevention of iron overload in hepcidin deficiency states, including hereditary hemochromatosis and β-thalassemias. In the mouse model of β-thalassemia, transgenic hepcidin therapy improved iron overload as well as erythropoiesis suggesting that hepcidin deficiency or iron overload may adversely impact erythropoiesis in this disease. Hepcidin antagonists and inhibitors of hepcidin production may find utility in the treatment of iron-restricted anemias, alone or in combination with erythropoiesis-stimulating agents.

**Conclusion and perspectives**—The discovery of hepcidin and its role in iron homeostasis has revolutionized our understanding of the pathogenesis of iron overload and iron-restricted anemias, and has stimulated the development of new diagnostic and therapeutic modalities for these disorders. Important scientific questions still remain to be answered. Further work is required to elucidate the mechanisms of hepcidin regulation by iron and erythroid activity, to delineate the specific contribution of hepcidin excess to different forms of anemia of inflammation, to understand the structure and transport function of the hepcidin receptor ferroportin, to identify the mechanisms by which hepcidin binding triggers ferroportin internalization and degradation, and to define any activities of hepcidin beyond its role in iron homeostasis.
Acknowledgements—I am grateful for the advice and editorial assistance of Elizabeta Nemeth during the preparation of this manuscript. Our contribution to this field would not have been possible without the collaboration of many colleagues all over the world and the generous support of the National Institutes of Health, and especially the National Institute of Diabetes and Digestive and Kidney Diseases.

Authorship—Tomas Ganz researched and prepared the manuscript and its figures. He is an officer and part-owner of Intrinsic LifeSciences LLC, La Jolla, California, USA, a company involved in the development of hepcidin-related diagnostics. He holds a patent dealing with hepcidin regulation by soluble hemojuvelin and has filed for a patent on hepcidin agonists for therapeutic use. In the last two years, he provided consultations for Xenon Pharmaceuticals and Ortho/Centocor. He has received grant funding from Amgen, Baxter and Roche Foundation for Anemia Research.
Reference List


Tables

Table 1: Human and mouse mutations that cause systemic iron dysregulation

<table>
<thead>
<tr>
<th>Component</th>
<th>Putative role</th>
</tr>
</thead>
<tbody>
<tr>
<td>transferrin</td>
<td>iron carrier, presents extracellular iron to hepatocytes for sensing</td>
</tr>
<tr>
<td>TfR1</td>
<td>cellular iron uptake, signals holotransferrin concentration through HFE</td>
</tr>
<tr>
<td>TfR2</td>
<td>holotransferrin sensing, partially redundant to TfR1/HFE</td>
</tr>
<tr>
<td>HFE</td>
<td>binds to TfR1 and TfR2, signals TfR1 occupancy</td>
</tr>
<tr>
<td>hemojuvelin</td>
<td>BMP co-receptor, enhances BMP signaling, target of TMPRSS6</td>
</tr>
<tr>
<td>neogenin</td>
<td>binds to hemojuvelin, enhances BMP signaling</td>
</tr>
<tr>
<td>TMPRSS6</td>
<td>negative regulator, decreases BMP signaling by cleaving hemojuvelin</td>
</tr>
<tr>
<td>Smad4</td>
<td>conveys BMP signal to the hepcidin transcription complex</td>
</tr>
<tr>
<td>BMP6</td>
<td>iron-specific ligand of the BMP receptor, increased by hepatic iron</td>
</tr>
</tbody>
</table>

Table 2: Hepcidin and iron disorders

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Genes mutated</th>
<th>Hepcidin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hereditary hemochromatosis</td>
<td>HFE, TfR2, HJV, hepcidin</td>
<td>Low or inappropriately normal, despite iron load</td>
</tr>
<tr>
<td>(hepcidin deficiency)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hereditary hemochromatosis</td>
<td>Ferroportin</td>
<td>High, reflects iron load, very rare</td>
</tr>
<tr>
<td>(hepcidin resistance)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferroportin disease</td>
<td>Ferroportin</td>
<td>Insufficiently studied</td>
</tr>
<tr>
<td>Iron-refractory iron deficiency</td>
<td>TMPRSS6</td>
<td>High or inappropriately high normal, despite iron deficiency</td>
</tr>
<tr>
<td>anemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypotransferrinemia</td>
<td>Transferrin</td>
<td>Low unless transfused with plasma</td>
</tr>
<tr>
<td>β-thalassemia intermedia</td>
<td>β-globin</td>
<td>Low unless transfused</td>
</tr>
<tr>
<td>Chronic hepatitis C, alcoholic</td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>liver disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemia of inflammation</td>
<td></td>
<td>High or inappropriately normal, despite anemia and hypoferremia</td>
</tr>
<tr>
<td>Anemia of chronic kidney diseases</td>
<td></td>
<td>High or inappropriately normal, despite anemia and hypoferremia</td>
</tr>
</tbody>
</table>
Figure 1: Hepcidin interaction with ferroportin controls the major iron flows into plasma. Iron flows and reservoirs are depicted in blue, iron in hemoglobin is in red, and hepcidin and its effect is shown in orange.
Figure 2: A current model of regulation of hepcidin transcription by iron. Iron as holotransferrin is shown in orange, iron sensors and associated molecules are in grey, BMP receptor and its transduction pathway in shades of blue, the ligands and co-receptors of the BMP receptor in shades of green, and the negative regulator protease in purple. Molecules whose ablation was shown to cause iron dysregulation are marked by asterisks.
Hepcidin and iron regulation, ten years later

Tomas Ganz